GSK reported year-end 2010 results today, including sales of Promacta for ITP in US, EU, and other countries- LGND receives a 4.4% royalty on sales. Here are the numbers (estimates from my pound to US $ conversion):
4q10: $15.8m (increase from 4q09 sales of $8.2m)
full year 2010: $48.0m (increase from 2009 sales of $20.6m)
Royalties to LGND should come to about $0.9m for 4q10 and $2.1m for full-year 2010. These should continue to incrementally improve as sales ramp up in Europe (launched April 2010) and Japan (launching first quarter 2011). However, large increases in sales would come with approval in new indications- GSK will report clinical data for cancer and Hepatitis C in 2011 that should provide clarity.
4q10: $15.8m (increase from 4q09 sales of $8.2m)
full year 2010: $48.0m (increase from 2009 sales of $20.6m)
Royalties to LGND should come to about $0.9m for 4q10 and $2.1m for full-year 2010. These should continue to incrementally improve as sales ramp up in Europe (launched April 2010) and Japan (launching first quarter 2011). However, large increases in sales would come with approval in new indications- GSK will report clinical data for cancer and Hepatitis C in 2011 that should provide clarity.
RSS Feed
